COPD Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies

  • ID: 4439893
  • Report
  • Region: Asia Pacific
  • 120 Pages
  • GBI Research
1 of 5
COPD Asia-Pacific Market will be Valued at $6.7 Billion in 2023, Growing from $3.8 Billion in 2016 at a CAGR of 8.7%

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Nycomeds
  • Pearl Therapeutics
  • MORE

Summary

Chronic obstructive pulmonary disease (COPD) is a term that refers to a large group of lung diseases characterized by obstruction of airflow that interferes with normal breathing. COPD occurs most often in older adults, but can also affect middle-aged people. It is not common in younger adults, as their lungs are still in a healthy state, and it takes several years for COPD to develop. There are two main forms of COPD: chronic bronchitis, which involves a long-term cough with mucus; and emphysema, which involves damage to the lungs over time.

Asia-Pacific (APAC) chronic obstructive pulmonary disease (COPD) market is forecast to grow from around $3.8 billion in 2016 to over $6.5 billion in 2023, at a compound annual growth rate (CAGR) of around 8.7%. Over the forecast period the prevalence of COPD is expected to increase significantly across the APAC markets, mainly due to an increase in the smoking population, as the disease is more common among smokers (Lim et al., 2015).

Existing COPD therapies are aimed at managing the frequency and severity of the symptoms, and none have been shown to modify long-term disease progression. Roflumilast, which is the only targeted therapy available in the COPD market, has significant anti-inflammatory effects. However, the dosing of roflumilast is limited due to its side effects, which means that the therapeutic benefit is marginal.

The report "COPD Therapeutics in Asia-Pacific Markets to 2023 Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies" detailing the key points driving the COPD market in the five Asia-Pacific markets: India, China, Australia, South Korea and Japan.

In particular, this report provides the following:

  • Provides an introduction to COPD, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognosis for patients. An analysis of current treatment algorithms and options are also included..
  • Offers detailed analysis of the drugs currently marketed for COPD, detailing their key characteristics, including safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, pricing, and overall competitive strength.
  • Provides detailed analysis of the pipeline for COPD, by stage of development, molecule type, program type, mechanism of action and molecular target.
  • Provides detailed analysis of recent clinical trials in this indication by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Provides detailed analysis of key market drivers and barriers for the COPD market.

Scope

  • The COPD Asia-Pacific market will be valued at $6.7 billion in 2023, growing from $3.8 billion in 2016 at a CAGR of 8.7%.
  • Bronchodilators and ICS therapies dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?
  • Do branded therapies show continuous growth, and are they facing competition from generics?
  • How will branded therapies be affected by upcoming pipeline therapies?
  • The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
  • What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?
  • Various drivers and barriers will influence the market over the forecast period.
  • What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?
  • What factors are most likely to drive the market in these countries?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the COPD market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the COPD pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict COPD market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as analysis of the contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Nycomeds
  • Pearl Therapeutics
  • MORE

1 Table of Contents

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.4.1 Pathophysiology
2.5 Diagnosis
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Options
2.8.1 Treatment Algorithm

3 Marketed Products
3.1 Overview
3.2 Bronchodilator Combination Therapy
3.2.1 Brimica/Duaklir Genuair (aclidinium/formoterol) - AstraZeneca
3.2.2 Spiolto/Stiolto Respimat (tiotropium/olodaterol) - Boehringer Ingelheim
3.2.3 Ultibro (glycopyrronium/indacaterol) - Novartis
3.2.4 Anoro Ellipta (umeclidinium/vilanterol) - GlaxoSmithKline/Theravance
3.2.5 Combivent (ipratropium/albuterol) - Boehringer Ingelheim
3.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy
3.3.1 Symbicort (budesonide/formoterol) - AstraZeneca
3.3.2 Seretide/Advair/Adoair (salmeterol/fluticasone) - GlaxoSmithKline
3.3.3 Relvar/Breo (fluticasone and vilanterol) - GlaxoSmithKline/Theravance
3.4 Bronchodilator Monotherapy
3.4.1 Spiriva (tiotropium) - Boehringer Ingelheim
3.4.2 Foradil (formoterol) - Novartis
3.4.3 Onbrez/Arbeela/Arcapta (indacaterol) - Novartis
3.4.4 Seebri /Tovanor (glycopyrronium) - Novartis
3.4.5 Striverdi Respimat (olodaterol) - Boehringer Ingelheim
3.5 Alternative therapy
3.5.1 Daxas/Daliresp (roflumilast) - Nycomeds
3.5.2 Marketed Products Heatmap

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline Distribution by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Mepolizumab - GlaxoSmithKline
4.4.2 Benralizumab - AstraZeneca and MedImmune
4.4.3 PT003 - AstraZeneca/Pearl Therapeutics
4.4.4 PT010 - AstraZeneca/Pearl Therapeutics
4.4.5 Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate -GlaxoSmithKline
4.4.6 CHF-5993 (beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide) - Chiesi Farmaceutici S.p.A.
4.5 Heatmap for Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Phase
5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Phase
5.3 Clinical Trial Duration
5.3.1 Clinical Trial Duration by Molecule Type
5.3.2 Clinical Trial Duration by Molecular Target
5.4 Competitive Clinical Trials Metrics Analysis

6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Active Pipeline
7.1.2 Promising Late-Stage Pipeline Products Can Change Treatment Paradigm
7.1.3 Increasing Awareness of COPD
7.1.4 Aging Population
7.2 Barriers
7.2.1 Sales Erosion by Generics
7.2.2 Growing Competition
7.2.3 Low Diagnosis Rates

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Phase I
9.1.4 Phase II
9.1.5 Phase III
9.1.6 Pre-registration
9.2 Market Forecasts to 2023
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Bibliography
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer

List of Tables
Table 1: COPD Therapeutics Market, Global, Licensing Deals Value, 2006-2017
Table 2: COPD Therapeutics Market, Global, Co-development Deals Value, 2006-2017
Table 3: COPD Therapeutics Market, Global, All Pipeline Products, Discovery, 2017
Table 4: COPD Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 5: COPD Therapeutics Market, Global, All Pipeline Products, Phase I, 2017
Table 6: COPD Therapeutics Market, Global, All Pipeline Products, Phase I, 2017
Table 7: COPD Therapeutics Market, Global, All Pipeline Products, Phase III, 2017
Table 8: COPD Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
Table 9: COPD Therapeutics Market, Asia-Pacific, Market Forecast, 2016-2023
Table 10: COPD Therapeutics Market, India, Market Forecast, 2016-2023
Table 11: COPD Therapeutics Market, China, Market Forecast, 2016-2023
Table 12: COPD Therapeutics Market, Australia, Market Forecast, 2016-2023
Table 13: COPD Therapeutics Market, South Korea, Market Forecast, 2016-2023
Table 14: COPD Therapeutics Market, Japan, Market Forecast, 2016-2023

List of Figures
Figure 1: COPD Therapeutics Market, Treatment Algorithm of COPD
Figure 2: COPD Market, Global, Moderate-to-Severe COPD Marketed Products Heatmap, Efficacy and Safety, 2017
Figure 3: COPD Market, Global, Very Severe COPD Marketed Products Heatmap, Efficacy and Safety, 2017
Figure 4: COPD Therapeutics Market, Global, Pipeline, 2017
Figure 5: COPD Therapeutics Market, Global, Pipeline by Molecular Target, 2017
Figure 6: Pipeline for COPD Therapeutics by Molecular Target and Stage of Development, Global, 2017
Figure 7: COPD Therapeutics Market, APAC, Mepolizumab Market ($m), 2019-2023
Figure 8: COPD Therapeutics Market, APAC, Benralizumab Market ($m), 2020-2023
Figure 9: COPD Therapeutics Market, APAC, PT003 Market ($m), 2018-2023
Figure 10: COPD Therapeutics Market, APAC, PT010 Market ($m), 2019-2023
Figure 11: COPD Therapeutics Market, APAC, FF/UMEC/VI Market ($m), 2018-2023
Figure 12: COPD Therapeutics Market, APAC, CHF-5993 Market ($m), 2020-2023
Figure 13: COPD Market, Global, Pipeline Heatmap, Efficacy, 2017
Figure 14: COPD Therapeutics Market, Global, Competitor Matrix for Efficacy and Safety of Marketed and Pipeline Products, 2017
Figure 15: COPD Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016
Figure 16: COPD Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016
Figure 17: COPD Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016
Figure 18: COPD Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016
Figure 19: COPD Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016
Figure 20: COPD Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016
Figure 21: COPD Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016
Figure 22: COPD Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016
Figure 23: COPD Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016
Figure 24: COPD Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 25: COPD Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 26: COPD Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2016-2023
Figure 27: COPD Therapeutics Market, India, Treatment Patterns (million), 2016-2023
Figure 28: COPD Therapeutics Market, India, Annual Cost of Therapy ($), 2016-2023
Figure 29: COPD Therapeutics Market, India, Market Size ($m), 2016-2023
Figure 30: COPD Therapeutics Market, China, Treatment Patterns (million), 2016-2023
Figure 31: COPD Therapeutics Market, China, Annual Cost of Therapy ($), 2016-2023
Figure 32: COPD Therapeutics Market, China, Market Size ($bn), 2016-2023
Figure 33: COPD Therapeutics Market, Australia, Treatment Patterns (million), 2016-2023
Figure 34: COPD Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016-2023
Figure 35: COPD Therapeutics Market, Australia, Market Size ($m), 2016-2023
Figure 36: COPD Therapeutics Market, South Korea, Treatment Patterns (million), 2016-2023
Figure 37: COPD Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016-2023
Figure 38: COPD Therapeutics Market, South Korea, Market Size ($m), 2016-2023
Figure 39: COPD Therapeutics Market, Japan, Treatment Patterns (million), 2016-2023
Figure 40: COPD Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016-2023
Figure 41: COPD Therapeutics Market, Japan, Market Size ($m), 2016-2023
Figure 42: COPD Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2017
Figure 43: COPD Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017
Figure 44: COPD Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 45: COPD Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2017
Figure 46: COPD Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2017
Figure 47: COPD Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2017
Figure 48: COPD Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017
Figure 49: COPD Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017
Figure 50: COPD Therapeutics Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006-2017
Figure 51: COPD Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • GlaxoSmithKline
  • Novartis
  • Nycomeds
  • Pearl Therapeutics
  • Theravance
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll